ClinicalTrials.gg
CompletedNCT02257632TIDE AMDUpdated May 7, 2019Results posted

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

A Phase 4 interventional study of Ranibizumab 0.5 mg and Aflibercept 2 mg in Wet Age-Related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
77th of 124
41 · median 64
Started
2015
with 6 others
Phase 4
33 of 125
none open now
Registered
93rd of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 77th largest by enrollment of the 124 interventional ones that give a count, is one of 7 that started in 2015, is one of 33 in phase 4, and was the 93rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of the study was to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in treatment naïve wet neovascular Age-related Macular Degeneration (wAMD) patients in a detailed time course.

Read the detailed description

A planned study visit schedule was established at the time of baseline visit (day 1) for all patients. Study assessments for patients were performed at screening visit, baseline (day 1), day 2, day 8 (± 1 day to allow for flexibility in scheduling) and as of day 15 through to day 169 at biweekly visits.

03

Conditions studied

  • Wet Age-Related Macular Degeneration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual impairment predominantly due to neovascular AMD.
  • Active, newly diagnosed, untreated, angiographically documented, CNV lesion (i.e. leakage on fluorescein angiography plus intraretinal, subretinal or sub-RPE fluid on OCT) secondary to neovascular AMD in line with SmPC of ranibizumab and aflibercept

Exclusion criteria

Exclusion Criteria:

  • Stroke or myocardial infarction less than 3 months prior to screening.
  • Presence of uncontrolled systolic blood pressure or diastolic blood pressure
  • Type 1 or Type 2 diabetes mellitus
  • Use of any systemic anti-VEGF drugs
  • Use of systemic or inhaled for at least 30 consecutive days within 3 months prior to screening.
  • Women who are pregnant or breast feeding or who are menstruating and capable of becoming pregnant* and not practicing a medically approved method of

For either eye:

  • Any active periocular or ocular infection or inflammation
  • Uncontrolled glaucoma
  • Neovascularization of the iris or neovascular glaucoma
  • History of treatment with any anti-angiogenic drugs

For study eye:

  • Atrophy or fibrosis involving the center of the fovea at the time of screening or baseline.
  • Cataract (if causing significant visual impairment), planned cataract surgery during the study period, vitrectomy, aphakia, glaucoma surgery, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization of any other cause than wAMD
  • Irreversible structural damage within 0.5 disc diameter of the center of the macula
  • Any intraocular procedure (including cataract surgery, Yttrium-Aluminum-Garnet capsulotomy) within 3 months prior to baseline or anticipated within the next 6 months following baseline.
  • Use of intravitreal or topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening.

For fellow eye

  • Retinal or choroidal neovascularization or macula edema of any cause

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Group 1

    6 monthly intravitreal injections of 0.5 mg ranibizumab

    Drug: Ranibizumab 0.5 mg

  • Experimental
    Group 2

    3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab

    Drug: Ranibizumab 0.5 mg · Drug: Aflibercept 2 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase

    The AUC was calculated using the trapezoidal rule, where all available measurement between Day 1 and Week 12 were used. The AUC was standardized by dividing the calculated value by the number of days from first to last measurement.

    Time frame: Baseline up to Week 12 visit (Days 1, 2, 8, 15, 29, 43, 57, 71, 85)

Secondary outcomes

  1. Systemic VEGF-A Protein Levels From Study Week 12 to 24

    Systemic VEGF-A protein levels in patients switching from monthly 2 mg aflibercept injections to monthly 0.5 mg ranibizumab compared to patients treated with monthly 0.5 mg ranibizumab from baseline (standardized area under the curve)

    Time frame: From study week 12 to 24 (Days 85, 99, 113, 127, 141, 155, 169)

  2. Systemic VEGF-A Levels From Study Week 12 to 24 (Change From Baseline)

    Adjustment of systemic VEGF-A levels of patients switching from aflibercept to ranibizumab to levels comparable to baseline or to levels comparable as in patients treated from baseline with ranibizumab

    Time frame: From study week 12 to 24

07

Results

Posted May 7, 2019

Participant flow

The study included adult patients with active, newly diagnosed, and untreated wAMD. A total of 40 patients were treated at 6 study sites across Germany. Patients were treated in an outpatient setting.

Participant flow — Overall Study
MilestoneRanibizumabAflibercept and Ranibizumab
Started1922
Full analysis set (fas)1921
Safety set (saf)1921
Per-protocol set (pps)1720
Completed1819
Not completed13
Withdrew: Withdrawal by subject01
Withdrew: Adverse event12

Outcome measures

PrimaryStandardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase

The AUC was calculated using the trapezoidal rule, where all available measurement between Day 1 and Week 12 were used. The AUC was standardized by dividing the calculated value by the number of days from first to last measurement.

Time frame:
Baseline up to Week 12 visit (Days 1, 2, 8, 15, 29, 43, 57, 71, 85)
Reported as:
Mean · pg/mL
Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase
pg/mLRanibizumabAflibercept and Ranibizumab
Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase18.78 ± 8.46033.95 ± 7.659
Statistical analysis
  • Ranibizumab vs Aflibercept and Ranibizumab · ANCOVA · p = <0.0001 (missing Baseline VEGF-A level covariate values were imputed by the mean value of non-missing Baseline VEGF-A level from all other patients) · Mean difference (final values): -14.98 · 95% CI -19.64 to -10.32including treatment group and center as fixed effect factors and Baseline VEGF-A as a covariate
SecondarySystemic VEGF-A Protein Levels From Study Week 12 to 24

Systemic VEGF-A protein levels in patients switching from monthly 2 mg aflibercept injections to monthly 0.5 mg ranibizumab compared to patients treated with monthly 0.5 mg ranibizumab from baseline (standardized area under the curve)

Time frame:
From study week 12 to 24 (Days 85, 99, 113, 127, 141, 155, 169)
Reported as:
Mean · pg/mL
Systemic VEGF-A Protein Levels From Study Week 12 to 24
pg/mLRanibizumabAflibercept and Ranibizumab
Systemic VEGF-A Protein Levels From Study Week 12 to 2417.93 ± 5.31629.07 ± 7.863
Statistical analysis
  • Ranibizumab vs Aflibercept and Ranibizumab · ANCOVA · p = < 0.0001 (missing Baseline VEGF-A level covariate values were imputed by the mean value of non-missing Baseline VEGF-A level from all the patients with values) · Mean difference (final values): -11.46 · 95% CI -15.98 to -6.94including treatment group and center as fixed effect factors and Baseline VEGF-A as a covariate
SecondarySystemic VEGF-A Levels From Study Week 12 to 24 (Change From Baseline)

Adjustment of systemic VEGF-A levels of patients switching from aflibercept to ranibizumab to levels comparable to baseline or to levels comparable as in patients treated from baseline with ranibizumab

Time frame:
From study week 12 to 24
Reported as:
Mean · pg/ml
Systemic VEGF-A Levels From Study Week 12 to 24 (Change From Baseline)
pg/mlRanibizumabAflibercept and Ranibizumab
Change from Baseline at Week 12-1.37 ± 5.36923.73 ± 13.700
Change from Baseline at Week 14-1.00 ± 6.12821.93 ± 15.638
Change from Baseline at Week 16-0.01 ± 4.67519.26 ± 16.432
Change from Baseline at Week 181.99 ± 5.58211.61 ± 10.844
Change from Baseline at Week 201.62 ± 6.4604.84 ± 11.065
Change from Baseline at Week 220.66 ± 8.1092.45 ± 8.543
Change from Baseline at Week 24-1.18 ± 3.6640.96 ± 9.553

Adverse events

Collected over 28 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab (Up to Month 3)0/19 (0%)3/19 (15.8%)14/19 (73.7%)
Ranibizumab (After Month 3)0/19 (0%)0/19 (0%)9/19 (47.4%)
Aflibercept and Ranibizumab (Up to Month 3 - Aflibercept)0/21 (0%)1/21 (4.8%)17/21 (81%)
Aflibercept and Ranibizumab (After Month 3 - Ranibizumab)0/21 (0%)3/21 (14.3%)17/21 (81%)
Most frequent serious events
Most frequent serious events
EventRanibizumab (Up to Month 3)Ranibizumab (After Month 3)Aflibercept and Ranibizumab (Up to Month 3 - Aflibercept)Aflibercept and Ranibizumab (After Month 3 - Ranibizumab)
Retinal pigment epithelial tearEye disorders1/190/190/210/21
PneumoniaInfections and infestations1/190/190/210/21
Bone cystMusculoskeletal and connective tissue disorders1/190/190/210/21
Benign lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/190/190/210/21
Atrial fibrillationCardiac disorders0/190/191/211/21
Cardiac failure congestiveCardiac disorders0/190/190/211/21
Optic nerve cuppingEye disorders0/190/190/211/21
Most frequent other events
Showing 10 of 96
Most frequent other events
EventRanibizumab (Up to Month 3)Ranibizumab (After Month 3)Aflibercept and Ranibizumab (Up to Month 3 - Aflibercept)Aflibercept and Ranibizumab (After Month 3 - Ranibizumab)
Conjunctival haemorrhageEye disorders3/191/195/212/21
Viral upper respiratory tract infectionInfections and infestations3/192/192/214/21
Back painMusculoskeletal and connective tissue disorders2/190/190/210/21
Choroidal neovascularisationEye disorders0/190/191/212/21
Foreign body sensation in eyesEye disorders0/190/192/210/21
Vitreous detachmentEye disorders0/190/190/212/21
Sensation of foreign bodyGeneral disorders0/190/192/210/21
Intraocular pressure increasedInvestigations0/191/191/212/21
Photosensitivity reactionSkin and subcutaneous tissue disorders0/190/192/210/21
Aortic valve diseaseCardiac disorders1/190/190/210/21

Baseline characteristics

Full Analysis Set (FAS)

Age, Continuous
Age, Continuous(Years)RanibizumabAflibercept and RanibizumabTotal
Mean74.3 ± 5.5075.4 ± 8.9474.9 ± 7.43
Sex/Gender, Customized
Sex/Gender, Customized(Participants)RanibizumabAflibercept and RanibizumabTotal
Female111021
Male81119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RanibizumabAflibercept and RanibizumabTotal
Caucasian192140
08

Study locations

6 sites
  • Novartis Investigative Site
    Koeln, 50924, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    München, 80336, Germany
  • Novartis Investigative Site
    München, 81675, Germany
  • Novartis Investigative Site
    Osnabrück, 49076, Germany
  • Novartis Investigative Site
    Regensburg, 93042, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Mar 2017, 23 months.

Results were first posted in May 2019, 2 years 1 month after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 23 months is below that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 6, 2014
StartActual
Apr 8, 2015
Primary completionActual
Mar 20, 2017
CompletionActual
Jun 8, 2017
Results first posted
May 7, 2019
Last update
May 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02257632
Responsible party
Sponsor
First posted
Oct 6, 2014
Start date
Apr 8, 2015
Primary completion
Mar 20, 2017
Completion
Jun 8, 2017
Results posted
May 7, 2019
Last update
May 7, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion